AJ303 is a novel compound under development for the treatment of idiopathic pulmonary fibrosis (IPF). It decreased IPF-related inflammatory cytokines, such as IL-6, MCP1, and GM-CSF in vitro, that delays the progression of pulmonary fibrosis in bleomycin-induced pulmonary injury model in mice.

AJ303 has a favorable plasma to pulmonary ratio of tissue distribution after oral administration. Its potential efficacy in treating patients with IPF will be investigated clinically in 2021.

Current Pipeline

  • 60% 60%
  • 40% 40%
  • 30% 30%
  • 15% 15%
  • 10% 10%


We look forward to further discussions with you.
Please fill out the form, and we will get right back to you.



B405, No. 18, Siyuan St., Zhongzheng Dist., Taipei City 100, Taiwan (R.O.C.)

13 + 11 =